24/7 Market News Snapshot 19 February, 2025 – Pulmonx Corporation Common Stock (NASDAQ:LUNG)
DENVER, Colo., 19 February, 2025 (247marketnews.com) – (NASDAQ:LUNG) are discussed in this article.
Pulmonx Corporation is experiencing a notable surge in its stock performance, currently trading at $7.415 after opening at $6.89, representing a 6.08% increase. The heightened trading volume of 568.18K shares indicates a growing investor interest, likely fueled by positive market sentiment surrounding the company’s recent advancements and financial results. Analysts are closely observing the stock’s performance for potential resistance levels and future price actions, with a sustained breakout suggesting further upside potential.
In parallel, Pulmonx has reported exceptional financial results for the fourth quarter and full year ending December 31, 2024, highlighting a worldwide revenue of $83.8 million, which translates to a 22% year-over-year growth. The fourth quarter alone saw record revenue of $23.8 million, marking a 23% increase from the previous year. U.S. revenues contributed $15.9 million, up 16%, while international revenues escalated to $7.9 million, showcasing a remarkable 42% growth.
Steve Williamson, President and CEO of Pulmonx, expressed pride in the company’s achievements and emphasized their strategic focus on expanding their market presence and enhancing patient care workflows. The recent pilot launch of the LungTraX™ software platform is expected to bolster their growth trajectory as they move into 2025 and beyond.
Looking forward, Pulmonx anticipates a revenue target between $96 million and $98 million for 2025, underscoring their commitment to innovating treatment options for patients with chronic obstructive pulmonary disease (COPD). Through initiatives such as their educational partnership with the American Lung Association, Pulmonx is dedicated to increasing awareness and improving the quality of life for individuals suffering from severe emphysema, positioning themselves as a leader in advanced lung treatment solutions.